SCHEMBL14224809

SCHEMBL14224809

CCCCOc1cccnc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 5/20 0.56
CYP2C9 P11712 4/20 0.56
CYP1A2 P05177 4/20 0.56
PDE5A O76074 3/20 0.48
PDE4A P27815 3/20 0.48
PDE4B Q07343 3/20 0.48
PDE4C Q08493 3/20 0.48
PDE4D Q08499 3/20 0.48
CYP19A1 P11511 3/20 0.47
CHRNB2 P17787 3/20 0.46
CHRNA4 P43681 3/20 0.46
MCHR1 Q99705 1/20 0.45
CYP2D6 P10635 4/20 0.45
CHRNB1 P11230 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNB3 Q05901 1/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8126961 0.94 CYP1A2 (0.50) CYP2C19CYP2C9CYP1A2PDE5APDE4A
SCHEMBL27684835 0.93 PDE5A (0.50) CYP2C19CYP2C9CYP1A2PDE5APDE4A
Hydrochloric Acid SCHEMBL28282489 0.91 PDE5A (0.49) CYP2C19CYP2C9CYP1A2PDE5APDE4A
SCHEMBL6655861 0.90 CHRNB2 (0.51) CYP2C19CYP2C9CYP1A2PDE5APDE4A
Formaldehyde SCHEMBL27812370 0.85 GRM5 (0.48) CYP2C19CYP2C9CYP1A2PDE5APDE4A
SCHEMBL7245296 0.85 CHRNB2 (0.46) CYP2C19CYP2C9CYP1A2PDE5APDE4A
SCHEMBL19342481 0.84 CHRNB2 (0.47) CYP2C19CYP2C9CYP1A2PDE5APDE4A
SCHEMBL8325639 0.82 ALDH1A1 (0.52) PDE5ACHRNB2CHRNA4CHRNB1CHRNB4
SCHEMBL31461865 0.82 ALDH1A1 (0.52) PDE5ACHRNB2CHRNA4CHRNB1CHRNB4
SCHEMBL1536664 0.81 NCF1 (0.48) CYP2C19CYP2C9CYP1A2CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107690281-A Cystic fibrosis transmembrane transduction modulator modulators 弗特克斯药品有限公司 2018-02-13 CN disclosed
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027147-A1 Biarylurea derivatives CDK6, CDK4, CCNI CYP2C19 759/4885CYP2C9 1010/4885CYP1A2 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.